Health TrialsbyHealthPanel

Hyperthermia Combined With Hydrogen Peroxide Microneedle Patch for Viral Warts

ConditionWarts
Trial statusRecruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
Age6-65
SponsorFirst Hospital of China Medical University

About this trial

Hyperthermia treatment (hyperthermia) refers to treating diseases with temperature (39-45 ° C) beyond normal body temperature,. It has been reported that local warming at 44 ° C is able to effectively mobilize the body's immunity and clear HPV infected lesions, such as condyloma acuminatum and verruca vulgaris, etc. Significant progress has been made in the application of hyperthermia for viral skin diseases. Clinically, the addition of hydrogen peroxide solution can enhance the efficacy of hyperthermia in treating HPV infection. As a common transdermal drug delivery method, microneedles can increase drug penetration and thereby further improve treatment outcomes. Based on these findings, this study aims to explore an adjunctive approach to hyperthermia for treating viral warts to further enhance therapeutic efficacy.

This study employs a randomized, parallel-group, assessor-blinded design. Participants will be randomly assigned to three groups: hyperthermia alone, hyperthermia combined with microneedle patch (loaded with 0.9% saline), and hyperthermia combined with hydrogen peroxide microneedle patch (experimental group). An adaptive design will be adopted. The sample size is estimated at 70 participants per group, accounting for a potential 20% dropout rate. Interim analyses will be conducted during follow-up, and enrollment will be stopped when a positive result is reached for the primary efficacy endpoint (cure rate), at which point the sample size will be adjusted accordingly.

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Age 6-65 years, male or female;

Clinically diagnosed with common warts, palmar/plantar/digital warts (≥1 lesion), with a Physician's Wart Assessment score ≥2 (0: no visible wart, no further treatment required; 1: visible wart, diameter <3 mm; 2: single wart diameter ≥3 mm and <6 mm; 3: single wart diameter ≥6 mm);

The subject or legal guardian is able to understand and sign the informed consent form and agrees to participate in the study.

Disqualifiers

Subjects presenting with atypical warts clinically;

Subjects with immune dysfunction or autoimmune diseases;

Pregnant or breastfeeding women;

Subjects who have received human papillomavirus (HPV) vaccination within the past 6 months;

Trial design

Design model

Parallel

Treatments tested in this trial

  • 3% hydrogen peroxide solution

    Drug

    Dressing: Like the Local Hyperthermia Group, use a microneedle patch loaded with 3% hydrogen peroxide . Irradiation: For seven sessions in three weeks, use simulated infrared light (without heat) with the same frequency as the Local Hyperthermia Group. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts.

  • 0.9 % saline

    Drug

    Dressing: Like the Local Hyperthermia Group, use a microneedle patch loaded with 0.9% saline. Irradiation: For seven sessions in three weeks, use simulated infrared light (without heat) with the same frequency as the Local Hyperthermia Group. Local Hyperthermia treats the target warts(largest and most severe warts), while medication addresses all warts.

  • Hyperthermia at 44℃

    Device

    The infrared hyperthermia device was used as follows: based on the thermal tolerance of different body surface areas, the surface temperature was set to 44 °C ± 1 °C. The lesion was disinfected with alcohol. After the skin had dried, the patient's most painful or largest wart was selected as the target lesion and treated with 44 °C hyperthermia. The treatment was administered for three consecutive days (sessions), each lasting 30 minutes. After an interval of 7-10 days, the same target lesion received two consecutive days (sessions) of treatment, followed by one session every 7-10 days thereafter. For patients with multiple lesions, only one target lesion was treated using the above protocol, while the remaining lesions received no intervention.

  • Microneedle patch

    Device

    Purpose: To facilitate drug loading. Instructions:Add an appropriate amount of 3% hydrogen peroxide solution or 0.9% sodium chloride solution into the corresponding chamber. Apply the microneedle patch to the wart and secure it with tape. Press the raised part of the aluminum film sequentially with fingers until the chamber fully collapses and makes contact with the skin. After one hour of contact, dispose of the patch in a medical waste container.

Treatment groups

210 Participants
are divided into 3 treatment groups
Group A: Hyperthermia at 44°CExperimental treatment 2 interventions
Group B: Hyperthermia combined with microneedle patch (loaded with 0.9% saline)Experimental treatment 3 interventions
Group C: Hyperthermia combined with hydrogen peroxide microneedle patchExperimental treatment 3 interventions

Trial outcomes

Primary outcomes

1

Complete clearance rate of warts

The complete clearance rate was defined as the proportion of patients with lesions that completely disappeared within 6 months of completing all treatments.

Time frame
6 months after the first time of treatment.
2

Time to complete clearance

Median duration from first treatment to complete resolution (days)

Time frame
6 months after the first time of treatment.
3

Recurrence rate of warts

Complete clearance was defined as the proportion of patients with complete disappearance of lesions within 6 months of completion of all treatments, and recurrence was the proportion of patients with recurrence of lesions at the cured lesion site within 6 and 12 months after treatment.

Time frame
Recurrence was the proportion of patients with reappearance of lesions at previously cleared sites within 6 months after treatment.

Secondary outcomes

1

Changes in the size and number of warts at different points in time

Time frame
At months 1, 3, and 6
2

Occurrence of adverse events

Occurrence of adverse events (short - and long-term adverse reactions) (e.g. blisters, erythema, nail changes, ulcers/scars, hyperpigmentation, hypopigmentation, erosion)

Time frame
During treatment and follow-up
3

Treatment-related pain intensity

Pain assessed by Visual Analog Scale (VAS) ranging from 0 (no pain) to 10 (worst imaginable pain)

Time frame
During each treatment session (Day 1, 2, 3, 10, 11, 18, 19)
4

Time to first wart clearance

Time frame
At months 1, 3, and 6

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

First Hospital of China Medical University

Lead sponsor

Source ClinicalTrials.gov
Apply now